OverviewSuggest Edit

Aerie Pharmaceuticals, Inc., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of ophthalmic diseases. It focuses on the development of products for the pharmaceutical treatment of glaucoma. The Company’s lead product candidate, AR-13324, is the first of a new dual action drug class that reduces the eye’s fluid inflow while also increasing fluid outflow through the trabecular meshwork, which is the eye’s main fluid drain, all in a highly effective single drop per day. Aerie’s PG324 fixed combination of AR-13324 with latanoprost is a first-in-class glaucoma therapy to lower intraocular pressure by reducing fluid inflow while also opening both of the eye’s fluid drains. This product candidate offers the convenience of two drugs in one eye drop.

TypePublic
Founded2005
HQIrvine, US
Websiteaeriepharma.com
Employee Ratings5

Latest Updates

Employees (est.) (Feb 2019)160
Job Openings13
Share Price (Mar 2019)$46.8 (-4%)

Key People/Management at Aerie Pharmaceuticals

Richard J. Rubino

Richard J. Rubino

CFO
Casey C. Kopczynski

Casey C. Kopczynski

Chief Research Officer and Co-Founder
Thomas A. Mitro

Thomas A. Mitro

President and Chief Operating Officer
Gerald D. Cagle

Gerald D. Cagle

Independent Director
Murray Goldberg

Murray Goldberg

Member of the Board of Directors
Show more

Aerie Pharmaceuticals Office Locations

Aerie Pharmaceuticals has offices in Irvine, Durham, Bedminster Township and Dublin
Irvine, US (HQ)
2030 Main Street #1500
Bedminster Township, US
135 US-206 #15
Durham, US
4301 Emperor Blvd
Dublin, IE
28-32 Pembroke Street
Show all (4)
Report incorrect company information

Aerie Pharmaceuticals Financials and Metrics

Aerie Pharmaceuticals Revenue

USD

Net income (FY, 2018)

(232.6m)

EBIT (FY, 2018)

(209.7m)

Market capitalization (22-Mar-2019)

2.1b

Closing stock price (22-Mar-2019)

46.8

Cash (31-Dec-2018)

202.8m
Aerie Pharmaceuticals's current market capitalization is $2.1 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cost of goods sold

641.0k

General and administrative expense

10.3m30.6m44.5m73.6m120.6m

R&D expense

11.9m44.5m52.4m72.1m86.1m

Operating expense total

22.2m75.1m96.9m145.7m233.9m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

2.4m7.3m

Cost of goods sold

59.0k205.0k

Gross profit

2.4m7.1m

Gross profit Margin, %

98%97%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

69.6m85.6m91.1m197.9m197.6m202.8m

Accounts Receivable

399.0m2.7m

Inventories

618.0k1.1m1.9m4.0m10.1m

Current Assets

70.3m141.0m138.4m237.7m254.1m220.2m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

4.6m35.8m27.9m148.9m113.5m100.9m106.9m74.3m58.5m211.9m139.5m242.7m249.5m270.6m235.0m

Accounts Receivable

1.1m2.0m

Inventories

1.1m5.7m5.6m

Current Assets

7.1m65.8m57.3m171.7m171.0m159.9m156.6m120.7m108.2m256.5m210.2m310.0m341.2m295.5m246.8m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(31.1m)(48.1m)(74.4m)(99.1m)(145.1m)(232.6m)

Depreciation and Amortization

64.0k73.0k252.0k970.0k1.4m2.4m

Inventories

(9.7m)

Accounts Payable

2.0m551.0k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(20.9m)(6.7m)(18.5m)(31.6m)(17.2m)(36.0m)(54.0m)(22.7m)(45.9m)(69.7m)(25.8m)(54.2m)(40.7m)(95.7m)(181.1m)

Depreciation and Amortization

47.0k15.0k31.0k50.0k24.0k60.0k102.0k223.0k457.0k702.0k291.0k600.0k487.0k1.1m1.7m

Inventories

(969.0k)(5.5m)(5.3m)

Accounts Payable

1.0m208.0k1.4m2.3m(12.0k)(6.0k)2.4m(6.0k)(6.0k)(30.0k)(6.0m)
USDY, 2018

Financial Leverage

1.3 x
Show all financial metrics
Report incorrect company information

Aerie Pharmaceuticals News and Updates

Report incorrect company information

Aerie Pharmaceuticals Frequently Asked Questions

  • When was Aerie Pharmaceuticals founded?

    Aerie Pharmaceuticals was founded in 2005.

  • Who are Aerie Pharmaceuticals key executives?

    Aerie Pharmaceuticals's key executives are Richard J. Rubino, Casey C. Kopczynski and Thomas A. Mitro.

  • How many employees does Aerie Pharmaceuticals have?

    Aerie Pharmaceuticals has 160 employees.

  • Who are Aerie Pharmaceuticals competitors?

    Competitors of Aerie Pharmaceuticals include ANI Pharmaceuticals, Celyad and Sorrento Therapeutics.

  • Where is Aerie Pharmaceuticals headquarters?

    Aerie Pharmaceuticals headquarters is located at 2030 Main Street #1500, Irvine.

  • Where are Aerie Pharmaceuticals offices?

    Aerie Pharmaceuticals has offices in Irvine, Durham, Bedminster Township and Dublin.

  • How many offices does Aerie Pharmaceuticals have?

    Aerie Pharmaceuticals has 4 offices.